Literature DB >> 2360823

Oral ciprofloxacin treatment of Pseudomonas aeruginosa osteomyelitis.

M Dan1, Y Siegman-Igra, S Pitlik, R Raz.   

Abstract

Twenty-two adult patients with osteomyelitis due to Pseudomonas aeruginosa were enrolled in an open, prospective cooperative study to determine the efficacy of oral ciprofloxacin therapy in a dosage of 750 mg twice a day. Twenty patients received a complete course of treatment and could be assessed for efficacy. There were 12 men and 8 women, with a mean age of 55 years. Six patients had undergone previous, unsuccessful attempts at therapy. Eight patients had clinically important underlying conditions. The most common sites of infection were the sternum (six patients), hip (four patients), vertebrae (four patients), and tibia (two patients). Initial surgical debridement was performed in 18 of the 20 assessable patients. The mean duration of treatment was 2.85 months (range, 1 to 4 months), and that of the follow-up was 27 months (range, 6 to 52 months). Cure was achieved in 19 of the 20 (95%) patients. The only significant adverse effect (which prompted discontinuation of therapy) was severe nausea in one case. Oral ciprofloxacin coupled with adequate debridement is an effective, convenient, and safe therapy in patients with acute and subacute P. aeruginosa osteomyelitis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2360823      PMCID: PMC171704          DOI: 10.1128/AAC.34.5.849

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

2.  Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli.

Authors:  D N Gilbert; A D Tice; P K Marsh; P C Craven; L C Preheim
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

3.  Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis.

Authors:  A J Lesse; C Freer; R A Salata; J B Francis; W M Scheld
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

4.  Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis.

Authors:  R N Greenberg; A D Tice; P K Marsh; P C Craven; P M Reilly; M Bollinger; W J Weinandt
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

5.  Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis.

Authors:  M T Hessen; M J Ingerman; D H Kaufman; P Weiner; J Santoro; O M Korzeniowski; J Boscia; M Topiel; L M Bush; D Kaye
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

6.  Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin.

Authors:  R N Greenberg; D J Kennedy; P M Reilly; K L Luppen; W J Weinandt; M R Bollinger; F Aguirre; F Kodesch; A M Saeed
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

Review 7.  Ciprofloxacin: in vitro activity, mechanism of action, and resistance.

Authors:  C C Sanders
Journal:  Rev Infect Dis       Date:  1988 May-Jun

8.  Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa.

Authors:  B E Scully; H C Neu; M F Parry; W Mandell
Journal:  Lancet       Date:  1986-04-12       Impact factor: 79.321

9.  Ceftazidime as single-agent therapy for gram-negative aerobic bacillary osteomyelitis.

Authors:  M C Bach; D M Cocchetto
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

10.  Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.

Authors:  F Follath; M Bindschedler; M Wenk; R Frei; H Stalder; H Reber
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

View more
  10 in total

Review 1.  Antimicrobial agent therapy for Pseudomonas aeruginosa.

Authors:  J A Korvick; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

2.  Remission after treatment of osteoarticular infections due to Pseudomonas aeruginosa versus Staphylococcus aureus: a case-controlled study.

Authors:  Khalid Seghrouchni; Christian van Delden; Dennis Dominguez; Mohamed Benkabouche; Louis Bernard; Mathieu Assal; Pierre Hoffmeyer; Ilker Uçkay
Journal:  Int Orthop       Date:  2011-10-05       Impact factor: 3.075

Review 3.  Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  J A Balfour; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

Review 4.  Use of quinolones in osteomyelitis and infected orthopaedic prosthesis.

Authors:  D P Lew; F A Waldvogel
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 5.  Diagnosis and management of osteomyelitis. Decision analytic and pharmacoeconomic considerations.

Authors:  M Tavakoli; P Davey; B A Clift; H T Davies
Journal:  Pharmacoeconomics       Date:  1999-12       Impact factor: 4.981

Review 6.  Quinolones and osteomyelitis: state-of-the-art.

Authors:  D P Lew; F A Waldvogel
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 7.  Evaluation of quinolones in experimental animal models of infections.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 8.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

9.  Prolonged treatment of chronic Pseudomonas aeruginosa osteomyelitis with a combination of two effective antibiotics.

Authors:  R F Lucht; A Fresard; P Berthelot; F Farizon; G Aubert; G Dorche; G Bousquet
Journal:  Infection       Date:  1994 Jul-Aug       Impact factor: 3.553

10.  Ciprofloxacin release using natural rubber latex membranes as carrier.

Authors:  Heitor Dias Murbach; Guilherme Jaques Ogawa; Felipe Azevedo Borges; Matheus Carlos Romeiro Miranda; Rute Lopes; Natan Roberto de Barros; Alexandre Vinicius Guedes Mazalli; Rosângela Gonçalves da Silva; José Luiz Ferreira Cinman; Bruno de Camargo Drago; Rondinelli Donizetti Herculano
Journal:  Int J Biomater       Date:  2014-12-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.